EMYRIA LIMITED — Board/Management Information 2021

Feb 21, 2021

ASX Announcement

22/02/2021

Dr. Karen Smith, former Jazz Pharmaceuticals Chief Medical Officer and Global Head of Research & Development to Chair Emyria’s Strategic Advisory Board

Highlights:

• Experienced pharmaceutical expert, Dr. Karen Smith, M.D., Ph.D., M.B.A., L.L.M, will Chair Emyria’s Strategic Advisory Board

• Dr. Smith holds multiple Directorships with innovative pharmaceutical companies and was previously Chief Medical Officer and Global Head of Research & Development at Jazz Pharmaceuticals

• USA based Dr. Smith has overseen more than 100 clinical trials and 20 regulatory approvals in major global markets

• Appointment boosts Emyria’s global clinical trial and regulatory approval expertise to accelerate drug registration initiatives

• Appointment to support innovation across Emyria’s drug development programs and evidence-generating care models

Emyria Limited (ASX: EMD) (Emyria or the Company), a data-driven drug development company, is pleased to announce the appointment of global pharmaceutical expert, Dr. Karen Smith to Chair Emyria’s Strategic Advisory Board.

Emyria’s Managing Director, Dr. Michael Winlo , said: “We’re delighted to welcome Dr. Karen Smith to Chair our Strategic Advisory Board. Dr. Smith is a highly acclaimed and respected pharmaceutical executive, who has overseen multiple successful drug registrations.

Dr. Smith has held key Chief Executive Officer and Chief Medical Officer roles at some of the most innovative Biotech and Pharmaceutical development companies in the world including holding the role of CMO and Head of R&D at Jazz Pharmaceuticals, which recently acquired GW Pharma for $7.2B. GW’s FDA approved product is a formulation of CBD for a type of epilepsy.

We believe Dr. Smiths’ background in successful product registration and strategic partnerships in biopharma will benefit Emyria’s globally-focussed drug registration initiatives, including our EMD-003 product candidate for psychological distress and the symptoms of anxiety, depression and stress.”

1

==> picture [137 x 40] intentionally omitted <==

Global drug registration expertise across Biotech and Pharma Dr. Smith has overseen more than 100 clinical trials and more than 20 regulatory approvals leading to product launches across diverse therapeutic areas including neuroscience, rare disease, oncology, cardiology, dermatology, oncology and anti-infectives. In addition to R&D and pipeline development, Karen’s successful record of business development includes the acquisition of U.S. and international companies, divestitures and negotiating partnership deals between biotech and pharma.

==> picture [129 x 130] intentionally omitted <==

In addition to Emyria’s Scientific Advisory Board, Dr. Smith serves as Chief Medical Officer of Emergent BioSolutions - a multinational speciality biopharmaceutical company developing and manufacturing therapeutics and devices for public health threats, including COVID-19. Dr. Smith is also a Director at Antares Pharmaceuticals - developing novel drug delivery technologies and Sangamo Therapeutics and Acceleron Pharmaceuticals - both developing novel treatments for rare diseases, and TeeFib – developing novel treatments for Fibrosis.

Previously, Dr. Smith served as Executive Vice President, Global Head R&D and Chief Medical Officer of Jazz Pharmaceuticals , Inc., which recently acquired GW Pharmaceuticals for $7.2B USD.

Dr. Smith was also the founding Chief Executive Officer of the Minderoo Foundation’s “Eliminate Cancer Initiative” supported by Andrew Forrest and remains an advisor to that program.

Dr. Smith has also held senior leadership positions at Allergan plc, AstraZeneca and Bristol-Myers Squibb .

Dr. Smith earned an MD from the University of Warwick (UK), PhD in Molecular Oncology from UCLA (USA) and University of Western Australia (Australia), an MBA from the University of New England in Australia and LLM (Masters in Law) from the University of Salford (UK).

Dr. Karen Smith , said: “I’m passionate about supporting innovative ways to accelerate drug development. Emyria has built a unique clinical service and evidence-generating model that has the potential to accelerate drug development for patients with unmet needs. I look forward to assisting the team make progress on its global drug registration goals.”

Emyria’s Strategic Advisory Board will meet regularly to support Emyria’s drug development pipeline and also Emyria’s digital remote monitoring and Real-World Evidence (RWE) initiatives.

Dr. Smith, for advisory services, will receive a total of 1.5M options exercisable at $0.268 expiring 3 years from the date of issue, with one third vesting on issue and the remainder vesting over 2 years.

2

==> picture [137 x 40] intentionally omitted <==

Emyria’s first, globally-focussed drug development program is EMD-003 targeting unmet needs in mental health such as psychological distress and the symptoms of anxiety, depression and stress (see ASX announcements 25 Nov 20 and 05 Jan 21) . EMD-003 is an innovative cannabinoid-based medicine seeking registration as a Schedule 3 medicine with the Therapeutic Goods Administration’s (TGA) Australian Register of Therapeutic Goods (ARTG). Successful registration will require substantial evidence of quality, safety and effectiveness. The development of EMD-003 is informed by Emyria’s Real-World Evidence (RWE) and backed by unique intellectual property (IP).

This announcement has been approved and authorised for release by the Board of Emyria Limited.

For further information:

Dr Michael Winlo Lexi O’Halloran Managing Director Media/Investor Relations (08) 6559 2800 + 61 (0) 404 577 076 mwinlo@emyria.com lexi@janemorganmanagement.com.au

Andrew Williams Media Relations +61 (0) 412 614 125 andreww@proflemedia.com.au

About Emyria (www.emyria.com)

Emyria Limited is a data-backed, drug development company. Emyria’s Treatments target unmet needs and are focused on obtaining approval from major global regulators. Emyria’s drug development programs are informed by insights generated from extensive analysis of Emyria Data - deep, ethically-sourced clinical evidence that is gathered with patients across Emyria’s independent clinical services ( Emerald Clinics - www.emeraldclinics.com.au)

Emyria Data provides deep treatment insights and is therefore a source of unique IP, strategically designed drug development and personalised care programs.

Cautionary Note on Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for the Company, the company’s strategy, future operations, and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company’s ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company’s ability to obtain marketing approvals for its product candidates. In addition, the forward-looking statements included in this press release represents the Company’s views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date hereof.

3